Skip to content
2000
Volume 7, Issue 1
  • ISSN: 1872-2083
  • E-ISSN: 2212-4012

Abstract

Diseases caused by protozoan parasites are still an important health problem. These parasites can cause a wide spectrum of diseases, some of which are severe and have high morbidity or mortality if untreated. Since they are still uncontrolled, it is important to find novel drug targets and develop new therapies to decrease their remarkable social and economic impact on human societies. In the past years, human HSP90 has become an interesting drug target that has led to a large number of investigations both at state organizations and pharmaceutical companies, followed by clinical trials. The finding that HSP90 has important biological roles in some protozoan parasites like Plasmodium spp, Toxoplasma gondii and trypanosomatids has allowed the expansion of the results obtained in human cancer to these infections. This review summarizes the latest important findings showing protozoan HSP90 as a drug target and presents three patents targeting T. gondii, P. falciparum and trypanosomatids HSP90.

Loading

Article metrics loading...

/content/journals/biot/10.2174/1872208311307010002
2013-04-01
2025-10-03
Loading full text...

Full text loading...

/content/journals/biot/10.2174/1872208311307010002
Loading

  • Article Type:
    Research Article
Keyword(s): 17-AAG; geldanamycin; HSP90; patent; Plasmodium; therapy; Toxoplasma
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test